Company news

Island Pharmaceuticals Ltd news in 2024

Island Pharmaceuticals Ltd's news releases, calls and decks from 2024, newest first.

View company

US patent granted for ISLA-101

December 10, 2024

ISLA-101 shows anti-dengue activity in Phase 2a readout

November 26, 2024

Receipt of R&D tax refund for FY2024

November 21, 2024

Clinical trial progress update

November 18, 2024

Island completes $3.5m Placement

October 3, 2024

Phase 2a PROTECT clinical trial dosed & Investor webinar

October 2, 2024

Binding LOI for proposed acquisition of Galidesivir

September 10, 2024

ISLA-101 Phase 2a/b clinical trial progresses

August 6, 2024

Non-binding term sheet signed with BioCryst

July 2, 2024

Investor Presentation

June 3, 2024

New data leads to proposed ISLA-101 Phase 2 efficiencies

June 3, 2024

Grant funding to directly support Phase 2a trial

May 7, 2024

Investor Presentation - Asia Bio Partnering

April 22, 2024

Positive data from ISLA-101 Single Ascending Dose study

April 15, 2024

Security Class Reinstatement to Quotation ILAO

April 1, 2024

Security Class Suspension from Quotation ILAO

March 26, 2024

Island Pharmaceuticals to raise $1.95 million for ISLA-101 development

February 27, 2024

Prospectus

February 25, 2024

$1.95million Fully Underwritten Rights Issue

February 25, 2024

Island investor presentation

February 6, 2024

Dosing complete in ISLA-101 SAD study

February 5, 2024

Quarterly Activity Report and Appendix 4C

January 30, 2024

Third cohort dosed in ISLA-101 Single Ascending Dose study

January 19, 2024

Decks in 2024